These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 2863848)

  • 1. High-dose versus low-dose strategies in the treatment of schizophrenia.
    Kane JM; Rifkin A; Woerner M; Reardon G; Kreisman D; Blumenthal R; Borenstein M
    Psychopharmacol Bull; 1985; 21(3):533-7. PubMed ID: 2863848
    [No Abstract]   [Full Text] [Related]  

  • 2. Information processing and maintenance dose requirements in schizophrenia.
    Marder SR; Asarnow RF; Van Putten T
    Psychopharmacol Bull; 1988; 24(2):247-50. PubMed ID: 2905506
    [No Abstract]   [Full Text] [Related]  

  • 3. High-dose ziprasidone in treatment-resistant schizophrenia and affective spectrum disorders: a case series.
    Deutschman DA; Deutschman DH
    J Clin Psychopharmacol; 2007 Oct; 27(5):513-4. PubMed ID: 17873687
    [No Abstract]   [Full Text] [Related]  

  • 4. Antipsychotic medication in the treatment of schizophrenia.
    Kane JM
    Isr J Psychiatry Relat Sci; 1995; 32(1):30-7. PubMed ID: 7542642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effect of L-dopa on schizophrenia.
    Ogura C; Kishimoto A; Nakao T
    Curr Ther Res Clin Exp; 1976 Sep; 20(3):308-18. PubMed ID: 9266
    [No Abstract]   [Full Text] [Related]  

  • 6. [Report on an open investigation on bromperidol, a neuroleptic of the butyrophenone series].
    Fleischhauer J
    Int Pharmacopsychiatry; 1978; 13 Suppl 1():30-7. PubMed ID: 35476
    [No Abstract]   [Full Text] [Related]  

  • 7. ICI 204,636: a new atypical antipsychotic drug.
    Hirsch SR; Link CG; Goldstein JM; Arvanitis LA
    Br J Psychiatry Suppl; 1996 May; (29):45-56. PubMed ID: 8733823
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical correlates of antipsychotic polytherapy in patients with schizophrenia in Singapore.
    Sim K; Su A; Chan YH; Shinfuku N; Kua EH; Tan CH
    Psychiatry Clin Neurosci; 2004 Jun; 58(3):324-9. PubMed ID: 15149301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone.
    Kopala LC; Fredrikson D; Good KP; Honer WG
    Biol Psychiatry; 1996 Feb; 39(4):296-8. PubMed ID: 8645777
    [No Abstract]   [Full Text] [Related]  

  • 10. Amoxapine as an antipsychotic: comparative study versus haloperidol.
    Chaudhry IB; Husain N; Khan S; Badshah S; Deakin B; Kapur S
    J Clin Psychopharmacol; 2007 Dec; 27(6):575-81. PubMed ID: 18004123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic dosage reduction in treatment-resistant schizophrenic patients.
    Van Putten T; Marshall BD; Liberman R; Mintz J; Kuehnel TG; Bowen L; Aravagiri M; Marder SR
    Psychopharmacol Bull; 1993; 29(2):315-20. PubMed ID: 7904763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proceedings: Butaclamol in the treatment of schizophrenia--a comparison of two treatment methods.
    Imaz F; Ban TA; Lehmann HE
    Psychopharmacol Bull; 1976 Jan; 12(1):31-4. PubMed ID: 1826
    [No Abstract]   [Full Text] [Related]  

  • 13. High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction.
    Kawai N; Yamakawa Y; Baba A; Nemoto K; Tachikawa H; Hori T; Asada T; Iidaka T
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1009-14. PubMed ID: 16644082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frontal lobe tasks, antipsychotic medication, and schizophrenia syndromes.
    Himelhoch S; Taylor SF; Goldman RS; Tandon R
    Biol Psychiatry; 1996 Feb; 39(3):227-9. PubMed ID: 8837987
    [No Abstract]   [Full Text] [Related]  

  • 15. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial.
    Leiderman E; Zylberman I; Zukin SR; Cooper TB; Javitt DC
    Biol Psychiatry; 1996 Feb; 39(3):213-5. PubMed ID: 8837983
    [No Abstract]   [Full Text] [Related]  

  • 16. Serum cholesterol and treatment-resistance in schizophrenia.
    Boston PF; Dursun SM; Zafar R; Reveley MA
    Biol Psychiatry; 1996 Sep; 40(6):542-3. PubMed ID: 8879475
    [No Abstract]   [Full Text] [Related]  

  • 17. Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia.
    Levinson I; Levine S
    Biol Psychiatry; 1995 Aug; 38(3):198-200. PubMed ID: 7578667
    [No Abstract]   [Full Text] [Related]  

  • 18. The relationship of the brief psychiatric rating scale to neuropsychological deficits in phenothiazine-treated schizophrenics.
    Golden CJ; Carpenter B; Wilkening G; Ruedrich S; Chu CC; Graber B
    Psychopharmacol Bull; 1983; 19(3):513-7. PubMed ID: 6138799
    [No Abstract]   [Full Text] [Related]  

  • 19. Predictors of neuroleptic treatment response in acute schizophrenia: results of a treatment study with perazine.
    Gaebel W; Pietzcker A; Ulrich G; Schley J; Müller-Oerlinghausen B
    Pharmacopsychiatry; 1988 Nov; 21(6):384-6. PubMed ID: 2907645
    [No Abstract]   [Full Text] [Related]  

  • 20. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results.
    Haro JM; Suarez D; Novick D; Brown J; Usall J; Naber D;
    Eur Neuropsychopharmacol; 2007 Mar; 17(4):235-44. PubMed ID: 17137759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.